当前位置:首页 >财报库 > 报告详情

雅培Abbott Laboratories (ABT)2025年第三季度财报(10-Q)「NYSE」(英文版)(38页).pdf

上传人: 1****1 编号:987238 2025-12-09 38页 497.49KB

下载:

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934For the quarterly period ended September 30,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECUR

2、ITIESEXCHANGE ACT OF 1934For the transition period from toCommission File No.1-2189ABBOTT LABORATORIESAn Illinois CorporationI.R.S.Employer Identification No.36-0698440100 Abbott Park RoadAbbott Park,Illinois 60064-6400Telephone:(224)667-6100Securities Registered Pursuant to Section 12(b)of the Act:

3、Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which RegisteredCommon Shares,Without Par ValueABTNew York Stock ExchangeNYSE TexasIndicate by check mark whether the registrant:(l)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of l934duri

4、ng the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required t

5、o be submitted pursuant to Rule 405 ofRegulation S-T(229.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-a

6、ccelerated filer,a smaller reporting company,or anemerging growth company.See the definitions of“large accelerated filer,”“accelerated filer,”“smaller reporting company,”and“emerging growthcompany”in Rule 12b-2 of the Exchange Act.Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Small

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据《Data》标记内容,以下是Abbott Laboratories 2025年第三季度及九个月财务报告的要点概括: 1. **收入增长**:2025年第三季度净销售额为11.37亿美元,同比增长6.9%;前三季度净销售额为32.87亿美元,同比增长6.1%。 2. **业务板块表现**:医疗设备和成熟药品产品线销售额增长显著,分别增长12.5%和7.1%。诊断产品线因COVID-19检测相关销售下降和中国市场挑战,销售额下降6.6%。 3. **财务状况**:截至2025年9月30日,Abbott拥有现金及现金等价物7.51亿美元,总资产84.18亿美元。 4. **股东投资**:截至2025年9月30日,Abbott股东投资为51.26亿美元,同比增长7.6%。 5. **现金流**:前三季度经营活动产生的净现金为6.25亿美元,投资活动使用现金1.51亿美元,融资活动使用现金4.91亿美元。 6. **未来展望**:Abbott预计未来24个月内将确认约54%的剩余履约义务相关收入,随后12个月约17%,剩余部分将在之后确认。
**季度收益如何?** **销售增长动力何在?** **汇率变动影响几何?**
客服
商务合作
小程序
服务号
折叠